Everything we've seen

1. ·Nov 15, 11:34 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

2. ·Nov 15, 11:19 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

3. ·Nov 15, 11:04 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

4. ·Nov 15, 10:49 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

5. ·Nov 15, 10:34 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

6. ·Nov 15, 10:19 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

7. ·Nov 15, 10:04 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

8. ·Nov 15, 9:49 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

9. ·Nov 15, 9:34 AMstreamnews

   Should You Continue to Retain Bruker Stock in Your Portfolio?

   BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

10. ·Nov 15, 9:19 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

11. ·Nov 15, 9:04 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

12. ·Nov 15, 8:49 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

13. ·Nov 15, 8:34 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

14. ·Nov 15, 8:19 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

15. ·Nov 15, 8:05 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

16. ·Nov 15, 7:49 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

17. ·Nov 15, 7:34 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

18. ·Nov 15, 7:19 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

19. ·Nov 15, 7:04 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

20. ·Nov 15, 6:49 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

21. ·Nov 15, 6:34 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

22. ·Nov 15, 6:19 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

23. ·Nov 15, 6:05 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

24. ·Nov 15, 5:49 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

25. ·Nov 15, 5:34 AMstreamnews

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

26. ❖Nov 13, 12:14 PMnewsvia finnhub

    Here's Why You Should Retain NVST Stock in Your Portfolio for Now

    Envista's global expansion, new product launches and improving margins support growth, but competitive pressures and currency headwinds pose challenges.

27. ❖Nov 13, 10:18 AMnewsvia finnhub

    Should You Continue to Retain Bruker Stock in Your Portfolio?

    BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.

28. ?Nov 11, 5:00 PMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $703.05 > MA150 $558.60 (+25.9%), MA rising, 8.7% off 52w high, vol 0.44× avg

29. ?Nov 11, 5:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $703.05 > MA150 $558.60 (+25.9%), MA rising, 8.7% off 52w high, vol 0.44× avg

30. ❖Nov 10, 7:27 PMnewsvia finnhub

    Should You Buy Zoetis Stock At This Price?

    For questions about this article or underlying research, email help@trefis.com.

31. ?Nov 10, 2:15 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IDXX is down 1.54% with 90 minutes remaining — a meaningful but not outsized move. No news catalyst is present to explain the selloff, which cuts both ways: no fresh negative driver to sustain momentum, but also no catalyst for a reversal. The macro context (elevated DFF at 2.0σ above trend) is modestly negative for growth/defensive names like IDXX, as higher rates compress multiples for premium-priced veterinary diagnostics companies. However, at 1.54% down, the move hasn't reached the 2-5% threshold that would signal high-conviction directional flow. With 90 minutes left, there is time for continuation, but the lack of a news driver and the moderate magnitude suggest this could be consolidation or profit-taking rather than a sustained directional move. The elevated rate environment provides a mild headwind, but not enough conviction to call strong continuation. Probability sits just below the 0.5 threshold — no position triggered.

32. !Nov 10, 2:15 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    IDXX is down 1.54% with 90 minutes remaining — a meaningful but not outsized move. No news catalyst is present to explain the selloff, which cuts both ways: no fresh negative driver to sustain momentum, but also no catalyst for a reversal. The macro context (elevated DFF at 2.0σ above trend) is modestly negative for growth/defensive names like IDXX, as higher rates compress multiples for premium-priced veterinary diagnostics companies. However, at 1.54% down, the move hasn't reached the 2-5% threshold that would signal high-conviction directional flow. With 90 minutes left, there is time for continuation, but the lack of a news driver and the moderate magnitude suggest this could be consolidation or profit-taking rather than a sustained directional move. The elevated rate environment provides a mild headwind, but not enough conviction to call strong continuation. Probability sits just below the 0.5 threshold — no position triggered.

33. ❖Nov 10, 12:57 PMnewsvia finnhub

    Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?

    LH's specialty testing growth, AI-driven efficiencies and expanding margins support its outlook, though currency pressures and competition pose risks.

34. ?Nov 10, 12:05 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IDXX is down 2.21% intraday with no accompanying news catalyst visible, suggesting this is either broad market pressure or sector rotation rather than a company-specific event. The macro context shows DFF (fed funds) running 2.0σ above its 24-month trend, which is a mild headwind for growth/defensive names like IDXX (veterinary diagnostics) as elevated rates compress multiples on high-P/E stocks. With 220 minutes remaining there is meaningful time for the move to continue or reverse, so time is not a strong factor either way. The absence of a news catalyst and the moderate magnitude (2.21%) suggest this is real flow but not a panic-driven gap — continuation is plausible but not highly confident. No clear reversal signals are present in the data provided. Net assessment: slight lean toward continuation given elevated rate environment pressuring growth multiples and no headline-driven snap-back catalyst, but conviction is low.

35. !Nov 10, 12:05 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    IDXX is down 2.21% intraday with no accompanying news catalyst visible, suggesting this is either broad market pressure or sector rotation rather than a company-specific event. The macro context shows DFF (fed funds) running 2.0σ above its 24-month trend, which is a mild headwind for growth/defensive names like IDXX (veterinary diagnostics) as elevated rates compress multiples on high-P/E stocks. With 220 minutes remaining there is meaningful time for the move to continue or reverse, so time is not a strong factor either way. The absence of a news catalyst and the moderate magnitude (2.21%) suggest this is real flow but not a panic-driven gap — continuation is plausible but not highly confident. No clear reversal signals are present in the data provided. Net assessment: slight lean toward continuation given elevated rate environment pressuring growth multiples and no headline-driven snap-back catalyst, but conviction is low.

36. ?Nov 10, 10:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IDXX is down 2.88% with ~305 minutes remaining, a meaningful move suggesting real institutional selling pressure. No headlines are available to explain the drop, but absence of news does not negate the flow signal. The macro context shows DFF elevated 2.0σ above trend, which is modestly negative for growth/premium-multiple names like IDXX (a veterinary diagnostics company with high P/E), as elevated rates compress valuations and reduce discretionary spending appetite. However, with over 5 hours remaining in the session, the move is still early enough that continuation is plausible but not highly certain — there is ample time for both continuation and mean reversion. No clear reversal signal is present (no fade described, no reversal pattern noted). The setup is ordinary momentum without strong catalysts in either direction. Slight lean toward continuation given the size of the move and rate-sensitive sector headwind, but conviction is low, placing this at the lower boundary of the continuation range.

37. !Nov 10, 10:40 AMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    IDXX is down 2.88% with ~305 minutes remaining, a meaningful move suggesting real institutional selling pressure. No headlines are available to explain the drop, but absence of news does not negate the flow signal. The macro context shows DFF elevated 2.0σ above trend, which is modestly negative for growth/premium-multiple names like IDXX (a veterinary diagnostics company with high P/E), as elevated rates compress valuations and reduce discretionary spending appetite. However, with over 5 hours remaining in the session, the move is still early enough that continuation is plausible but not highly certain — there is ample time for both continuation and mean reversion. No clear reversal signal is present (no fade described, no reversal pattern noted). The setup is ordinary momentum without strong catalysts in either direction. Slight lean toward continuation given the size of the move and rate-sensitive sector headwind, but conviction is low, placing this at the lower boundary of the continuation range.

38. ❖Nov 9, 7:20 AMnewsvia finnhub

    Should You Continue to Hold TMO Stock in Your Portfolio?

    Thermo Fisher's accelerating organic growth, rising bioproduction demand and strong capital returns support its outlook, but macroeconomic risks and competition remain concerns.

39. ❖Nov 6, 8:10 PMnewsvia finnhub

    How IDEXX Stock Is Engineered To Make Money For You

    For questions about this article or underlying research, email help@trefis.com.

40. ❖Nov 6, 11:45 AMnewsvia finnhub

    3 Reasons Growth Investors Will Love Idexx (IDXX)

    Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

41. ❖Nov 6, 6:01 AMnewsvia finnhub

    Executive Vice President At IDEXX Laboratories Sells $2.74M Of Stock

    On November 5, a recent SEC filing unveiled that Michael Lane, Executive Vice President at IDEXX Laboratories (NASDAQ:IDXX) made an insider sell. What Happened: Lane's recent move involves selling 3,978 shares of

42. ❖Nov 6, 6:01 AMnewsvia finnhub

    Board Member At IDEXX Laboratories Sells $844K Of Stock

    A substantial insider sell was reported on November 5, by Daniel M Junius, Board Member at IDEXX Laboratories (NASDAQ:IDXX), based on the recent SEC filing. What Happened: Junius's recent move involves selling 1,200

43. ❖Nov 6, 6:01 AMnewsvia finnhub

    Major Decision: Sharon E Underberg Exercises Options, Realizing $3.35M At IDEXX Laboratories

    Sharon E Underberg, EVP at IDEXX Laboratories (NASDAQ:IDXX), reported a large exercise of company stock options on November 5, according to a new SEC filing. What Happened: Underberg, EVP at IDEXX Laboratories,

44. ❖Nov 5, 11:21 PMnewsvia finnhub

    Elanco Animal Health Reports Soon: How Has The Stock Reacted To Past Earnings?

    Elanco Animal Health (NYSE:ELAN) is scheduled to report its earnings on Friday, November 6, 2026. The company has a market value of about $12.6 billion. Over the last twelve months it generated $5.0 billion in revenue and $333 million in operating profit, with a net loss of $199 million.

45. ?Nov 5, 3:41 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 5 minutes remaining until the forced close, there is virtually no time for further continuation to develop meaningfully. Even a strong downward setup loses its edge this close to EOD. The move itself is significant (-4.49%), suggesting real selling pressure or a catalyst not reflected in available headlines, but at this point the move has already largely played out. The macro context (elevated DFF rate environment) is modestly negative for growth/premium-multiple names like IDXX, which could have contributed to today's selling, but that factor is already priced into the current level. With <5 minutes to close, end-of-day covering/rebalancing flows often create mean-reversion pressure rather than continuation. The asymmetry of the forced flatten at 3:45 PM ET means there is insufficient time to capture any further downside even if the thesis is correct. Probability set below 0.5 purely on time-remaining grounds — the setup is otherwise neutral-to-mildly bearish on fundamentals.

46. !Nov 5, 3:41 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    With only 5 minutes remaining until the forced close, there is virtually no time for further continuation to develop meaningfully. Even a strong downward setup loses its edge this close to EOD. The move itself is significant (-4.49%), suggesting real selling pressure or a catalyst not reflected in available headlines, but at this point the move has already largely played out. The macro context (elevated DFF rate environment) is modestly negative for growth/premium-multiple names like IDXX, which could have contributed to today's selling, but that factor is already priced into the current level. With <5 minutes to close, end-of-day covering/rebalancing flows often create mean-reversion pressure rather than continuation. The asymmetry of the forced flatten at 3:45 PM ET means there is insufficient time to capture any further downside even if the thesis is correct. Probability set below 0.5 purely on time-remaining grounds — the setup is otherwise neutral-to-mildly bearish on fundamentals.

47. ?Nov 5, 12:50 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IDXX is down ~4% today with no headline catalyst visible, suggesting this is either a broad market flush or institutional repositioning in a high-multiple healthcare/diagnostics name. The macro backdrop shows the fed funds rate printing 2.1σ above its 24-month trend at 3.88%, which is a headwind for high-P/E growth names like IDXX — elevated rates compress multiples and reduce risk appetite for expensive defensive growers. No news means no obvious binary event that could snap back sharply. With 175 minutes remaining, there is meaningful time for the move to extend further, but also time for a partial mean-reversion. IDXX is a low-beta, high-quality name that tends to attract dip buyers at extended intraday lows, limiting runaway downside. The 4% move is at the upper end of typical single-session ranges for this name, slightly increasing the probability that some of this move gets faded. On balance: momentum is modestly down-biased with limited conviction for a strong continuation — the rate environment supports continued pressure on valuation-sensitive names, but the quality of the company and absence of a negative catalyst argue against a sharp follow-through. Assigning a slim majority probability to continuation given the macro rate headwind and momentum.

48. !Nov 5, 12:50 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    IDXX is down ~4% today with no headline catalyst visible, suggesting this is either a broad market flush or institutional repositioning in a high-multiple healthcare/diagnostics name. The macro backdrop shows the fed funds rate printing 2.1σ above its 24-month trend at 3.88%, which is a headwind for high-P/E growth names like IDXX — elevated rates compress multiples and reduce risk appetite for expensive defensive growers. No news means no obvious binary event that could snap back sharply. With 175 minutes remaining, there is meaningful time for the move to extend further, but also time for a partial mean-reversion. IDXX is a low-beta, high-quality name that tends to attract dip buyers at extended intraday lows, limiting runaway downside. The 4% move is at the upper end of typical single-session ranges for this name, slightly increasing the probability that some of this move gets faded. On balance: momentum is modestly down-biased with limited conviction for a strong continuation — the rate environment supports continued pressure on valuation-sensitive names, but the quality of the company and absence of a negative catalyst argue against a sharp follow-through. Assigning a slim majority probability to continuation given the macro rate headwind and momentum.

49. ?Nov 5, 10:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IDXX is down 2.57% with ~305 minutes remaining, a meaningful move that suggests real selling pressure or institutional flow. No headlines are available to explain the drop, but absence of news doesn't disqualify continuation — the magnitude itself signals conviction. The macro context (DFF elevated 2.1σ above trend at 3.88%) reflects tighter-than-expected monetary conditions, which is modestly negative for high-multiple healthcare/diagnostics names like IDXX that are rate-sensitive. However, this macro signal is sector-generic and not a sharp catalyst. With over 5 hours remaining, there is ample time for the move to extend, but also for a mean-reversion bounce if no additional catalysts emerge. No reversal pattern is evident yet. Balancing the modest continuation bias from the move magnitude and mildly adverse rate environment against the absence of a strong directional catalyst, I assign a slight lean toward continuation into the close.

50. !Nov 5, 10:40 AMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    IDXX is down 2.57% with ~305 minutes remaining, a meaningful move that suggests real selling pressure or institutional flow. No headlines are available to explain the drop, but absence of news doesn't disqualify continuation — the magnitude itself signals conviction. The macro context (DFF elevated 2.1σ above trend at 3.88%) reflects tighter-than-expected monetary conditions, which is modestly negative for high-multiple healthcare/diagnostics names like IDXX that are rate-sensitive. However, this macro signal is sector-generic and not a sharp catalyst. With over 5 hours remaining, there is ample time for the move to extend, but also for a mean-reversion bounce if no additional catalysts emerge. No reversal pattern is evident yet. Balancing the modest continuation bias from the move magnitude and mildly adverse rate environment against the absence of a strong directional catalyst, I assign a slight lean toward continuation into the close.

51. ❖Nov 4, 3:35 AMnewsvia finnhub

    IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)

    IDEXX Laboratories lifts FY26 revenue guidance after strong Q3 results. Read here for a detailed investment analysis of IDXX stock.

52. ❖Nov 4, 1:07 AMnewsvia finnhub

    IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class

    IDEXX Laboratories has best-in-class diagnostics, high recurring revenue, and a robust innovation pipeline. Find out why IDXX stock is a buy.

53. ❖Nov 3, 6:22 PMnewsvia finnhub

    IDEXX Laboratories (IDXX) Q3 Earnings Leave Its Premium Valuation In Focus

    IDEXX Laboratories stock barely moved after its Q3 2026 report, edging up about 0.1% to around US$672. For a business trading on a rich P/E multiple of roughly 45x, that muted reaction might look like a shrug. It is not; the real story sits in the earnings power that is being used to justify that valuation. Quarterly revenue reached about US$1.2b and basic earnings per share came in just over US$4, underpinned by a trailing net profit margin of 25.4%. If you focus only on today’s tiny price...

54. ❖Nov 3, 1:04 PMnewsvia finnhub

    IDEXX Laboratories Delivered Strong Results Despite Lackluster Vet Visit Backdrop, UBS Says

    IDEXX Laboratories' (IDXX) latest results demonstrated its ability to sustain strong performance des

55. ?Nov 3, 9:51 AMdecisionconsidered

    Agent 20 — SIR Price/Volume — buy

    [not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-10-06 through 2026-10-30, IDXX carved out a well-defined price cluster ranging roughly $506–$576 on consistently subdued volume (ADV ~502K–824K, median well under 600K), forming a classic SIR low-volume consolidation zone. The 2026-10-30 bar ($551.21, 1.2M shares, -4.30%) was an elevated-volume shakeout within the cluster — not a distribution setup, as it was an isolated single session without follow-through net-negative sub-path. On 2026-11-02, IDXX exploded to $671.64 on 2.0M shares (volume z-score: +7.49 vs. trailing 20-day mean of 561K), launching the 2-D scatter dot decisively up-and-right, clear of the entire prior 20-day cluster — the textbook SIR cluster_break_up signature of fresh demand absorbing the float on a quantum volume expansion. Risks: The signal rests on a single extraordinary bar — the SIR methodology prizes multi-session path confirmation, so a failure to hold above the breakout level (~$620–$640) on the next 2–3 sessions on normalized volume would strongly suggest an exhaustion climax rather than a genuine cluster break. Additionally, the macro context flags a DFF print 2.2σ above trend on 2026-10-30, which, while not directly reactive to IDXX's Health Care sector, could tighten financial conditions and weigh on high-multiple growth names like IDXX if the rate shock broadens.

56. ❖Nov 3, 8:35 AMnewsvia finnhub

    Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $810

    Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from $805 to $810.

57. ❖Nov 3, 8:30 AMnewsvia finnhub

    Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors

    When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

58. ❖Nov 3, 8:22 AMnewsvia finnhub

    Company News for Nov 3, 2026

    Companies in The News Are: CNA, IDXX, VLO, MAR

59. ❖Nov 3, 8:13 AMnewsvia finnhub

    US Stock Market Today: S&P 500 Futures Slip On Firm Manufacturing And Jobs Focus

    The Morning Bull - US Market Morning Update Tuesday, Nov, 3 2026 US stocks are set for a softer open, with sentiment pulled in two directions by competing signals on growth and inflation. Strong US manufacturing data is the main force shaping the tone before the bell. The ISM Manufacturing PMI came in at 55.5 for October 2026, pointing to solid factory activity. At the same time, the S&P Global manufacturing PMI was revised to 54.9 with higher input costs, which keeps inflation concerns alive...

60. ❖Nov 3, 8:01 AMnewsvia finnhub

    Stock Market Today: Marvell’s $115 Billion Bet on Lumentum Backfires as Chip Stocks Drag the Nasdaq Lower

    Marvell and Lumentum sank after a $115 billion all-stock deal, chip stocks fell again and the Nasdaq lost 1.1%. Oil dropped about 8% on US-Iran talk hopes, Apple warned on margins and Palantir raised its outlook.

61. ❖Nov 3, 7:00 AMnewsvia finnhub

    UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $700

    UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $627 to $700.

62. ❖Nov 2, 7:55 PMnewsvia finnhub

    Review & Preview: Whiplash

    High hopes of an AI rally were dashed on Monday.

63. ❖Nov 2, 7:00 PMnewsvia finnhub

    IDEXX stock soars 21.9% after earnings beat and higher outlook

    The veterinary diagnostics company saw sales and profit grow more than Wall Street expected.

64. ❖Nov 2, 6:14 PMnewsvia finnhub

    Non-AI stock surges 20% after earnings beat and raised outlook

    IDEXX Laboratories raised its full-year earnings and revenue forecasts after stronger demand for its veterinary diagnostic products.

65. ?Nov 2, 5:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — buy

    [not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-10-06 through 2026-10-30, IDXX traced a tight price cluster roughly between $506 and $576 on uniformly subdued volume (median daily volume ~490K, well within the 20-day ADV of 561K), forming a classic SIR low-volume consolidation base. The 2026-10-30 session printed a notable down-day on elevated volume (1.2M, ~2.1× ADV), a potential shakeout or final flush of weak holders at $551.21. Today, 2026-11-02, the path exploded out of that cluster with a close of $671.64 — a +21.85% surge — on 1.9M shares (z-score of 7.35 vs. trailing 20-day mean), decisively clearing every prior closing price in the 20-day window on unprecedented demand. In SIR two-dimensional terms, the dot has vaulted far up and to the right of the entire prior cluster in a single session, the textbook signature of a cluster_break_up: fresh institutional demand absorbing the available float at a materially higher price. Risks: This is a single-bar event — the SIR methodology cautions that one extreme dot does not confirm a sustained path, and a failure to hold above the prior cluster top (~$576) in subsequent sessions would signal a false breakout and invalidate the bullish read. Additionally, the elevated 30-year mortgage rate (7.24%, 2.3σ above trend as of 2026-10-29) poses a macro headwind to Health Care names with capital-intensive veterinary/diagnostics clients, and any broad risk-off rotation could pull the stock back into the base before multi-session confirmation accrues.

66. ❖Nov 2, 5:19 PMnewsvia finnhub

    Earnings Calendar and Analysis for This Week (June 8-12)

    Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.

67. ❖Nov 2, 4:15 PMnewsvia finnhub

    US Equity Markets Mixed as Technology Sell-Off Continues, Crude Oil Prices Dip

    US equity indexes were mixed Monday amid declining crude oil prices and continued sell-off in the te

68. ❖Nov 2, 4:02 PMnewsvia finnhub

    IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook, Record ...

    IDEXX Laboratories Inc (IDXX) lifted full-year revenue and EPS guidance after 10% organic growth and nearly 5,800 premium instrument placements, even as US clinic visits declined.

69. ❖Nov 2, 3:58 PMnewsvia finnhub

    Sector Update: Healthcare Stocks Ease Late Afternoon

    Healthcare stocks eased late Monday afternoon with the NYSE Healthcare Index down 0.1% and the State

70. ❖Nov 2, 3:15 PMnewsvia finnhub

    Why IDEXX Stock Is Up 21.6% And What's Next

    IDEXX Laboratories reported Q3 2026 sales of US$1,214.24 million and net income of US$317.15 million, with both basic and diluted EPS from continuing operations above the prior year period. Management lifted full year 2026 revenue and EPS guidance while accepting a slightly softer operating margin range, noting a focus on expanding diagnostics adoption, integrating recent software and AI acquisitions, and supporting recurring revenue growth. This article will examine how IDEXX Laboratories'...

71. ❖Nov 2, 3:06 PMnewsvia finnhub

    S&P 500 Top Movers Today: IDXX Jumps 20.39%, LITE Drops 18.23%

    Today's S&P 500 top movers include IDEXX Laboratories up 20.39% and Lumentum down 18.23%, with other gainers above 5% and double-digit declines among several losers.

72. ❖Nov 2, 3:05 PMnewsvia finnhub

    Top Midday Gainers

    Inovio Pharmaceuticals (INO) shares surged Monday after the company's Friday announcement that the U

73. ❖Nov 2, 2:54 PMnewsvia finnhub

    IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund

    IDEXX Laboratories exploded higher on Monday, and millions of retirement savers felt it without ever picking the stock. How much it moved your 401(k) depends on a kind of hidden overlap most investors never think to check.

74. ❖Nov 2, 1:32 PMnewsvia finnhub

    IDEXX Soars 20% on Beat-and-Raise Quarter: “Early Innings of a Broad-Based Innovation Cycle”

    Key TakeawaysIDEXX Laboratories shares jumped 20% after a third-quarter beat and a raised 2026 outlook. New inVue Dx analyzers are driving recurring test revenue, with in-clinic consumables up 15% organically.

75. ❖Nov 2, 1:05 PMnewsvia finnhub

    S&P 500 Unusual Volume Movers for Nov. 2, 2026

    Nov. 2, 2026 scan of S&P 500 unusual-volume stocks: Reddit, West Pharmaceutical, Regeneron, Estée Lauder and IDEXX traded above their 50-day average volume.

76. ❖Nov 2, 12:50 PMnewsvia finnhub

    IDEXX Laboratories, Inc. Q3 2026 Earnings Call Summary

    Moby summary of IDEXX Laboratories, Inc.'s Q3 2026 earnings call

77. ❖Nov 2, 12:36 PMnewsvia finnhub

    S&P 500 Top Movers for Nov. 2, 2026: IDXX Gains 19.59%, LITE Falls 13.94%

    S&P 500 top movers for Nov. 2, 2026: IDEXX Laboratories rose 19.59% and Lumentum fell 13.94% during the session, highlighting the index's largest gains and losses.

78. ❖Nov 2, 12:02 PMnewsvia finnhub

    IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction

    IDEXX raised its 2026 earnings forecast, but it also trimmed its margin outlook. Here’s what is really behind the raise, and why testing demand isn’t the reason.

79. ❖Nov 2, 11:47 AMnewsvia finnhub

    Idexx Is Today’s Best S&P 500 Stock. It’s Defying an Industry Slump.

    Idexx Laboratories reported strong growth in veterinary diagnostics, offsetting sluggish industry demand.

80. ❖Nov 2, 11:28 AMnewsvia finnhub

    IDEXX (IDXX) Q3 2026 Earnings Call Transcript

    Diagnostics revenue surged 11% as premium instrument placements expanded globally.

81. ❖Nov 2, 11:13 AMnewsvia finnhub

    IDEXX Laboratories Q3 Earnings Call Highlights

    IDEXX Laboratories (NASDAQ:IDXX) reported third-quarter 2026 results marked by organic revenue growth, higher diagnostic utilization and expanded placement of its premium instruments, while raising its full-year revenue and earnings outlook. Chief Financial Officer Andrew Emerson said organic reven

82. ❖Nov 2, 10:37 AMnewsvia finnhub

    Charles River's Q3 Earnings on Deck: What's in Store for the Stock?

    CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.

83. ❖Nov 2, 10:36 AMnewsvia finnhub

    S&P 500 Opening Gap Movers for November 2, 2026

    S&P 500 stocks with notable opening gaps on November 2, 2026, including gap-up names such as IDXX, UAL and MAR, and gap-down names such as LITE, ORCL and MRVL.

84. ❖Nov 2, 10:30 AMnewsvia finnhub

    US Gap Movers: Top Gap-Up and Gap-Down Stocks in Today's Session

    Today's US gap movers include CLRO, EVGO, PERI and NVA on the gap-up list, while DRUG, JDZG, JAGX and SVRN lead the gap-down list.

85. ❖Nov 2, 9:23 AMnewsvia finnhub

    Idexx Labs Barks Up A Third-Quarter Beat; Can It Fetch This Next Bullish Move?

    Idexx Laboratories outperformed a shaky macro on Monday, beating third-quarter forecasts. Idexx stock surged.

86. ❖Nov 2, 8:36 AMnewsvia finnhub

    S&P 500 Premarket Movers Nov. 2, 2026: IDEXX and Fox Gain, Lumentum and T-Mobile Fall

    IDEXX Laboratories and Fox Corp. led S&P 500 premarket gainers on Nov. 2, 2026, while Lumentum and T-Mobile led the decliners.

87. ❖Nov 2, 8:32 AMnewsvia finnhub

    Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today

    Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.

88. ❖Nov 2, 8:30 AMnewsvia finnhub

    Idexx (IDXX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

    While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

89. ❖Nov 2, 8:18 AMnewsvia finnhub

    IDEXX Laboratories Shares Rise 2.57% as Q3 Earnings Beat Forecasts and FY2026 Guidance Increases

    IDEXX Laboratories Inc. (NASDAQ:IDXX) shares advanced 2.

90. ❖Nov 2, 8:17 AMnewsvia finnhub

    IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market

    IDEXX Laboratories beats Q3 2026 earnings and revenue estimates as diagnostic demand boosts growth and margins expand, prompting higher 2026 revenue and earnings guidance.

91. ❖Nov 2, 8:09 AMnewsvia finnhub

    Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic

    IDEXX tops Q3 estimates and lifts 2026 guidance as rising test intensity and global instrument sales offset softer U.S. veterinary clinic traffic.

92. ▣Nov 1, 7:00 PMjournaltarget

    Agent 5 — Dip Buyer (Evolving) closed long 1 @ $641.82 (+$117.28)

    Staged exit (1/2.0): close $641.82 ≥ target $624.15. Selling 1/3 sh, trailing remainder.

93. ▣Nov 1, 7:00 PMjournaltarget

    Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $645.76 (+$114.27)

    Staged exit (1/2.0): close $645.76 ≥ target $577.09. Selling 1/2 sh, trailing remainder.

94. ▣Nov 1, 7:00 PMjournaltarget

    Agent 5 — Dip Buyer (Evolving) closed long 1 @ $667.00 (+$142.46)

    Staged exit (1/2.0): close $667.00 ≥ target $624.15. Selling 1/2 sh, trailing remainder.

95. ▣Nov 1, 7:00 PMjournaltarget

    Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $641.82 (+$110.33)

    Staged exit (1/2.0): close $641.82 ≥ target $577.09. Selling 1/3 sh, trailing remainder.

96. ?Oct 30, 6:00 PMdecisionconsidered

    Agent 9 — Bear Equity — considered

    Stage 4: close $551.31 < MA150 $552.51 (-0.2%), MA falling, 28.4% off 52w high, vol 3.68× avg

97. ?Oct 30, 1:30 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IDXX is down 2.28% intraday, a meaningful move suggesting real selling pressure. However, several factors temper conviction on continuation: (1) No IDXX-specific headlines are present to explain the drop or sustain a narrative; the headlines are all about unrelated tickers (Cencora, Revvity, STERIS). (2) The macro context (elevated mortgage rates) is not directly relevant to IDXX, a veterinary diagnostics company — no meaningful sector tailwind or headwind from FRED data. (3) With 135 minutes remaining, there is time for either continuation or a mean-reversion bounce, and absent a news catalyst, late-session dip-buying in a quality name like IDXX is plausible. (4) A -2.28% move is at the lower bound of the 'meaningful' range — not a decisive flush that typically carries into close. Balancing these factors: the existing momentum is real and slightly favors continuation, but the absence of a catalyst and IDXX's quality/defensive profile (often bought on dips) prevent a high-conviction read. Probability sits just above the 0.5 threshold, warranting a position with tight stop discipline.

98. !Oct 30, 1:30 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    IDXX is down 2.28% intraday, a meaningful move suggesting real selling pressure. However, several factors temper conviction on continuation: (1) No IDXX-specific headlines are present to explain the drop or sustain a narrative; the headlines are all about unrelated tickers (Cencora, Revvity, STERIS). (2) The macro context (elevated mortgage rates) is not directly relevant to IDXX, a veterinary diagnostics company — no meaningful sector tailwind or headwind from FRED data. (3) With 135 minutes remaining, there is time for either continuation or a mean-reversion bounce, and absent a news catalyst, late-session dip-buying in a quality name like IDXX is plausible. (4) A -2.28% move is at the lower bound of the 'meaningful' range — not a decisive flush that typically carries into close. Balancing these factors: the existing momentum is real and slightly favors continuation, but the absence of a catalyst and IDXX's quality/defensive profile (often bought on dips) prevent a high-conviction read. Probability sits just above the 0.5 threshold, warranting a position with tight stop discipline.

99. ?Oct 26, 3:15 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IDXX is up 1.70% today, a meaningful but not outsized intraday move. However, with only 30 minutes remaining until the forced close, there is very limited runway for continuation even if the setup were strong. The macro backdrop is mildly unhelpful — a flattening yield curve (T10Y2Y at 1.6σ below trend) is not particularly constructive for growth/premium-multiple names like IDXX, which trades at a high valuation and is sensitive to discount-rate sentiment. No IDXX-specific news is present; the headlines are about Zoetis (a peer) and Baxter, neither of which provides a clear catalyst read. The absence of a catalyst means the move is likely flow/positioning-driven, which can persist but also fades into close as participants flatten. With 30 minutes left, the time decay on any momentum trade is severe — even a continuation probability that might be 0.52-0.55 with 90 minutes remaining compresses below 0.5 here. The risk/reward does not favor initiating a long with this little time and no supporting catalyst.

100. !Oct 26, 3:15 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     IDXX is up 1.70% today, a meaningful but not outsized intraday move. However, with only 30 minutes remaining until the forced close, there is very limited runway for continuation even if the setup were strong. The macro backdrop is mildly unhelpful — a flattening yield curve (T10Y2Y at 1.6σ below trend) is not particularly constructive for growth/premium-multiple names like IDXX, which trades at a high valuation and is sensitive to discount-rate sentiment. No IDXX-specific news is present; the headlines are about Zoetis (a peer) and Baxter, neither of which provides a clear catalyst read. The absence of a catalyst means the move is likely flow/positioning-driven, which can persist but also fades into close as participants flatten. With 30 minutes left, the time decay on any momentum trade is severe — even a continuation probability that might be 0.52-0.55 with 90 minutes remaining compresses below 0.5 here. The risk/reward does not favor initiating a long with this little time and no supporting catalyst.

101. ✓Oct 22, 11:01 AMdecisionacted

     Agent 8 — Dip Buyer (Peer-Aware) — pyramid

     Pyramid add-on fired at +10.05% unrealized. Added 1 sh @ $565.96 ($565.96). Position now 3 sh @ weighted avg $531.49.

102. ?Oct 22, 10:51 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IDXX is up 2.03% intraday, a meaningful move suggesting real institutional flow. There are no IDXX-specific headlines driving an obvious narrative catalyst, but absence of news is not disqualifying — this may be sector rotation, anticipatory positioning ahead of earnings, or broader healthcare/diagnostics flow. The macro context (2Y yields at 4.77, 2.1σ above trend) is a mild headwind for longer-duration growth names like IDXX, as elevated short rates can compress multiples on high-P/E diagnostics companies. However, this is a background factor rather than an acute reversal signal. With 295 minutes remaining, there is ample time for the move to continue or extend. No reversal pattern is evident from the data provided — price is simply up on the day with no fade signal. The setup is ordinary momentum with a mild macro headwind, warranting a modest continuation probability above 0.5 but not a high-conviction call. Sizing should reflect the borderline nature of this read.

103. !Oct 22, 10:51 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     IDXX is up 2.03% intraday, a meaningful move suggesting real institutional flow. There are no IDXX-specific headlines driving an obvious narrative catalyst, but absence of news is not disqualifying — this may be sector rotation, anticipatory positioning ahead of earnings, or broader healthcare/diagnostics flow. The macro context (2Y yields at 4.77, 2.1σ above trend) is a mild headwind for longer-duration growth names like IDXX, as elevated short rates can compress multiples on high-P/E diagnostics companies. However, this is a background factor rather than an acute reversal signal. With 295 minutes remaining, there is ample time for the move to continue or extend. No reversal pattern is evident from the data provided — price is simply up on the day with no fade signal. The setup is ordinary momentum with a mild macro headwind, warranting a modest continuation probability above 0.5 but not a high-conviction call. Sizing should reflect the borderline nature of this read.

104. ?Oct 16, 3:10 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IDXX is up 2.19% intraday with no attributable headline, suggesting either technical or institutional flow-driven move. However, with only 35 minutes remaining until the forced close cutoff, the time window is too narrow to expect meaningful additional upside beyond the already-achieved gain. The macro backdrop (mortgage rates at 7.4%, 3.3σ above trend) is not directly sector-relevant for IDXX (veterinary diagnostics), so it provides no tailwind or headwind. The absence of news is neutral, not disqualifying, but the combination of a move that has already realized most of its potential, very limited time remaining, and end-of-day profit-taking risk (longs locking in gains into the close) tilts the balance slightly against continuation. The 2.19% move is meaningful but not extreme enough to suggest a catalyst that would drive a sustained second leg. Probability falls just below the 0.5 threshold — fade risk into close marginally outweighs continuation.

105. !Oct 16, 3:10 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     IDXX is up 2.19% intraday with no attributable headline, suggesting either technical or institutional flow-driven move. However, with only 35 minutes remaining until the forced close cutoff, the time window is too narrow to expect meaningful additional upside beyond the already-achieved gain. The macro backdrop (mortgage rates at 7.4%, 3.3σ above trend) is not directly sector-relevant for IDXX (veterinary diagnostics), so it provides no tailwind or headwind. The absence of news is neutral, not disqualifying, but the combination of a move that has already realized most of its potential, very limited time remaining, and end-of-day profit-taking risk (longs locking in gains into the close) tilts the balance slightly against continuation. The 2.19% move is meaningful but not extreme enough to suggest a catalyst that would drive a sustained second leg. Probability falls just below the 0.5 threshold — fade risk into close marginally outweighs continuation.

106. ?Oct 16, 1:20 PMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IDXX is up 2.37% today with no attributable headline, suggesting institutional flow or a quiet sector rotation into high-quality healthcare/diagnostics names. The move is meaningful — someone with size is buying. However, several factors temper the continuation case: (1) No news catalyst to sustain a narrative into the close; (2) Macro backdrop shows mortgage rates at 3.3σ above trend (7.4%), which is broadly risk-negative and could weigh on high-multiple names like IDXX as rate sensitivity creeps into sentiment; (3) 145 minutes remaining is sufficient time for a continuation but also enough time for a fade if the initial buyer is done; (4) Without volume confirmation data, I cannot confirm this is a broad-participation move rather than a thin-volume spike. IDXX is not directly rate-sensitive (veterinary diagnostics), so the macro headwind is indirect and limited. On balance, ordinary momentum with no strong fading signal — probability sits just above the threshold. A tight stop at -1.5% limits downside if the move reverts.

107. !Oct 16, 1:20 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     IDXX is up 2.37% today with no attributable headline, suggesting institutional flow or a quiet sector rotation into high-quality healthcare/diagnostics names. The move is meaningful — someone with size is buying. However, several factors temper the continuation case: (1) No news catalyst to sustain a narrative into the close; (2) Macro backdrop shows mortgage rates at 3.3σ above trend (7.4%), which is broadly risk-negative and could weigh on high-multiple names like IDXX as rate sensitivity creeps into sentiment; (3) 145 minutes remaining is sufficient time for a continuation but also enough time for a fade if the initial buyer is done; (4) Without volume confirmation data, I cannot confirm this is a broad-participation move rather than a thin-volume spike. IDXX is not directly rate-sensitive (veterinary diagnostics), so the macro headwind is indirect and limited. On balance, ordinary momentum with no strong fading signal — probability sits just above the threshold. A tight stop at -1.5% limits downside if the move reverts.

108. ✓Oct 16, 9:41 AMdecisionacted

     Agent 5 — Dip Buyer (Evolving) — pyramid

     Pyramid add-on fired at +10.68% unrealized. Added 1 sh @ $560.61 ($560.61). Position now 3 sh @ weighted avg $524.54.

109. ▣Oct 15, 8:00 PMjournalstop

     Agent 9 — Bear Equity closed short 17 @ $560.50 (+$469.37)

     Short trailing stop: close $560.50 ≥ trailing floor $555.17 (trough × 1.10)

110. ?Oct 15, 10:10 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IDXX is up 2.52% with 335 minutes remaining (well into the session, but still meaningful time before the 3:45 PM forced close). The move represents real institutional conviction — no obvious catalyst in headlines, but absence of news is not disqualifying. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.6σ above trend, which is modestly headwind for rate-sensitive sectors; however, IDXX (veterinary diagnostics) is a high-quality growth compounder with relatively low direct rate sensitivity compared to pure financials or utilities. The elevated inflation expectations print does not present a strong reason to expect a fade specific to this name. With no reversal signal, no news-driven gap-and-crap pattern, and a clean upward move, momentum lean is mildly bullish into the close. Time remaining is ample. No strong reason to fade, so defaulting to modest continuation probability consistent with ordinary momentum without strong confirming signals.

111. !Oct 15, 10:10 AMsignalseverity 0.03

     Agent 7 — Day Trader — day_trade_skipped

     IDXX is up 2.52% with 335 minutes remaining (well into the session, but still meaningful time before the 3:45 PM forced close). The move represents real institutional conviction — no obvious catalyst in headlines, but absence of news is not disqualifying. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.6σ above trend, which is modestly headwind for rate-sensitive sectors; however, IDXX (veterinary diagnostics) is a high-quality growth compounder with relatively low direct rate sensitivity compared to pure financials or utilities. The elevated inflation expectations print does not present a strong reason to expect a fade specific to this name. With no reversal signal, no news-driven gap-and-crap pattern, and a clean upward move, momentum lean is mildly bullish into the close. Time remaining is ample. No strong reason to fade, so defaulting to modest continuation probability consistent with ordinary momentum without strong confirming signals.

112. ?Oct 13, 10:05 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IDXX is down 1.62% mid-session, a moderate but not extreme move. No news catalysts are present to explain the move, suggesting it may be technical or sector-driven flow. The macro context shows the 10Y-3M spread at 0.99 (1.6σ above trend), which is mildly positive for risk assets and slightly headwind for a defensive/growth name like IDXX — this doesn't strongly support a continued sell-off but doesn't contradict it either. With 340 minutes remaining (this appears to be early in the session given the large time remaining), there is ample time for the move to either continue or reverse. The move magnitude at -1.62% is below the 2-5% threshold where flow conviction becomes highly meaningful. The absence of a catalyst and the relatively modest decline suggest this could reflect broad market pressure or quiet sector rotation rather than a stock-specific breakdown with legs. No clear reversal signals are present, but no strong continuation pressure either. Assigning 0.5 as a neutral read — the setup meets the minimum threshold to act given the system's bounded risk profile, but conviction is low.

113. !Oct 13, 10:05 AMsignalseverity -0.02

     Agent 7 — Day Trader — day_trade_skipped

     IDXX is down 1.62% mid-session, a moderate but not extreme move. No news catalysts are present to explain the move, suggesting it may be technical or sector-driven flow. The macro context shows the 10Y-3M spread at 0.99 (1.6σ above trend), which is mildly positive for risk assets and slightly headwind for a defensive/growth name like IDXX — this doesn't strongly support a continued sell-off but doesn't contradict it either. With 340 minutes remaining (this appears to be early in the session given the large time remaining), there is ample time for the move to either continue or reverse. The move magnitude at -1.62% is below the 2-5% threshold where flow conviction becomes highly meaningful. The absence of a catalyst and the relatively modest decline suggest this could reflect broad market pressure or quiet sector rotation rather than a stock-specific breakdown with legs. No clear reversal signals are present, but no strong continuation pressure either. Assigning 0.5 as a neutral read — the setup meets the minimum threshold to act given the system's bounded risk profile, but conviction is low.

114. ✓Sep 24, 1:21 PMdecisionacted

     Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

     [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX (IDEXX Laboratories) is a fundamentally sound veterinary diagnostics company with a durable competitive moat and recurring revenue streams. The 10.6% dip from its 30-day high lacks any confirmed fundamental catalyst — no negative headlines, no insider sales, and no earnings-related guidance cut are evident. The drop appears macro/sector-driven rather than company-specific, as Health Care ranks mid-tier (4 of 11) in 30d relative strength with a slight positive sector tailwind vs. SPY over 30 days. Options flow is modestly constructive with a P/C ratio of 0.68 and near-normal z-scores (slightly elevated put z=0.50 likely reflects hedging rather than directional bearishness). Earnings are 39 days away, safely beyond the high-caution window.

115. ?Sep 24, 12:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

     [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX (IDEXX Laboratories) is a fundamentally sound veterinary diagnostics company with a durable competitive moat and recurring revenue streams. The 10.6% dip from its 30-day high lacks any confirmed fundamental catalyst — no negative headlines, no insider sales, and no earnings-related guidance cut are evident. The drop appears macro/sector-driven rather than company-specific, as Health Care ranks mid-tier (4 of 11) in 30d relative strength with a slight positive sector tailwind vs. SPY over 30 days. Options flow is modestly constructive with a P/C ratio of 0.68 and near-normal z-scores (slightly elevated put z=0.50 likely reflects hedging rather than directional bearishness). Earnings are 39 days away, safely beyond the high-caution window.

116. ?Sep 24, 11:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

     [not executed — reserve_floor_or_cash] IDXX (IDEXX Laboratories) is a fundamentally sound veterinary diagnostics company with a durable competitive moat and recurring revenue streams. The 10.6% dip from its 30-day high lacks any confirmed fundamental catalyst — no negative headlines, no insider sales, and no earnings-related guidance cut are evident. The drop appears macro/sector-driven rather than company-specific, as Health Care ranks mid-tier (4 of 11) in 30d relative strength with a slight positive sector tailwind vs. SPY over 30 days. Options flow is modestly constructive with a P/C ratio of 0.68 and near-normal z-scores (slightly elevated put z=0.50 likely reflects hedging rather than directional bearishness). Earnings are 39 days away, safely beyond the high-caution window.

117. ✓Sep 24, 7:04 AMdecisionacted

     Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

     IDXX (IDEXX Laboratories) is a fundamentally sound veterinary diagnostics company with a durable competitive moat and recurring revenue streams. The 10.6% dip from its 30-day high lacks any confirmed fundamental catalyst — no negative headlines, no insider sales, and no earnings-related guidance cut are evident. The drop appears macro/sector-driven rather than company-specific, as Health Care ranks mid-tier (4 of 11) in 30d relative strength with a slight positive sector tailwind vs. SPY over 30 days. Options flow is modestly constructive with a P/C ratio of 0.68 and near-normal z-scores (slightly elevated put z=0.50 likely reflects hedging rather than directional bearishness). Earnings are 39 days away, safely beyond the high-caution window.

118. ▢Sep 23, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $531.49

119. ▢Sep 23, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $531.49

120. ?Sep 23, 6:02 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     IDXX (IDEXX Laboratories) is a fundamentally strong, high-quality compounder in veterinary diagnostics with durable recurring revenue and strong market positioning — no company-specific bad news, guidance cuts, or accounting issues are evident in the available filings or news. The 19.1% drawdown from the 30-day high appears macro-driven rather than fundamental: the 5-year forward inflation expectation (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and high-multiple growth stocks like IDXX. However, the absence of any news headlines and sparse 10-Q metrics make it difficult to confirm near-term earnings trajectory, and elevated inflation expectations could sustain multiple compression pressure over the 90-day horizon.

121. !Sep 23, 6:02 PMsignalseverity 0.11

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     IDXX (IDEXX Laboratories) is a fundamentally strong, high-quality compounder in veterinary diagnostics with durable recurring revenue and strong market positioning — no company-specific bad news, guidance cuts, or accounting issues are evident in the available filings or news. The 19.1% drawdown from the 30-day high appears macro-driven rather than fundamental: the 5-year forward inflation expectation (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and high-multiple growth stocks like IDXX. However, the absence of any news headlines and sparse 10-Q metrics make it difficult to confirm near-term earnings trajectory, and elevated inflation expectations could sustain multiple compression pressure over the 90-day horizon.

122. ?Sep 23, 4:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

123. !Sep 23, 4:20 PMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

124. ?Sep 23, 3:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

125. !Sep 23, 3:20 PMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

126. ?Sep 23, 2:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

127. !Sep 23, 2:21 PMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

128. ?Sep 23, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

129. !Sep 23, 1:20 PMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

130. ?Sep 23, 12:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

131. !Sep 23, 12:20 PMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

132. ?Sep 23, 11:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

133. !Sep 23, 11:20 AMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

134. ?Sep 23, 10:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

135. !Sep 23, 10:21 AMsignalseverity 0.10

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

136. ?Sep 23, 7:00 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

137. !Sep 23, 7:00 AMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

138. ?Sep 22, 6:02 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     IDXX (IDEXX Laboratories) is a fundamentally strong, high-quality compounder in veterinary diagnostics with durable recurring revenue and strong market positioning — no company-specific bad news, guidance cuts, or accounting issues are evident in the available filings or news. The 19.1% drawdown from the 30-day high appears macro-driven rather than fundamental: the 5-year forward inflation expectation (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and high-multiple growth stocks like IDXX. However, the absence of any news headlines and sparse 10-Q metrics make it difficult to confirm near-term earnings trajectory, and elevated inflation expectations could sustain multiple compression pressure over the 90-day horizon.

139. !Sep 22, 6:02 PMsignalseverity 0.13

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     IDXX (IDEXX Laboratories) is a fundamentally strong, high-quality compounder in veterinary diagnostics with durable recurring revenue and strong market positioning — no company-specific bad news, guidance cuts, or accounting issues are evident in the available filings or news. The 19.1% drawdown from the 30-day high appears macro-driven rather than fundamental: the 5-year forward inflation expectation (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and high-multiple growth stocks like IDXX. However, the absence of any news headlines and sparse 10-Q metrics make it difficult to confirm near-term earnings trajectory, and elevated inflation expectations could sustain multiple compression pressure over the 90-day horizon.

140. ?Sep 22, 4:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

141. !Sep 22, 4:21 PMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

142. ?Sep 22, 3:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

143. !Sep 22, 3:20 PMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

144. ?Sep 22, 2:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

145. !Sep 22, 2:21 PMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

146. ?Sep 22, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

147. !Sep 22, 1:20 PMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

148. ?Sep 22, 12:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

149. !Sep 22, 12:21 PMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

150. ?Sep 22, 11:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

151. !Sep 22, 11:20 AMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

152. ?Sep 22, 10:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

153. !Sep 22, 10:21 AMsignalseverity 0.14

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

154. ?Sep 22, 7:00 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

155. ?Sep 21, 6:02 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     IDXX (IDEXX Laboratories) is a fundamentally strong, high-quality compounder in veterinary diagnostics with durable recurring revenue and strong market positioning — no company-specific bad news, guidance cuts, or accounting issues are evident in the available filings or news. The 19.1% drawdown from the 30-day high appears macro-driven rather than fundamental: the 5-year forward inflation expectation (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and high-multiple growth stocks like IDXX. However, the absence of any news headlines and sparse 10-Q metrics make it difficult to confirm near-term earnings trajectory, and elevated inflation expectations could sustain multiple compression pressure over the 90-day horizon.

156. ?Sep 21, 4:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

157. ?Sep 21, 3:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

158. ?Sep 21, 2:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

159. ?Sep 21, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

160. ?Sep 21, 12:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

161. ?Sep 21, 11:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

162. ?Sep 21, 10:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

163. ▢Sep 15, 8:00 PMjournal

     Agent 7 — Day Trader opened long 5 @ $519.38

164. ▣Sep 15, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 5 @ $513.88 (-$27.50)

     EOD forced close — day trader never carries overnight

165. ▢Sep 13, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 1 @ $524.54

166. ▢Sep 13, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 1 @ $524.54

167. ▣Sep 9, 8:00 PMjournalstop

     Agent 4 — Dip Buyer (Frozen) closed long 1 @ $506.49 (-$46.95)

     intraday stop sweep

168. ▢Aug 26, 8:00 PMjournal

     Agent 4 — Dip Buyer (Frozen) opened long 1 @ $553.44

169. ▣Aug 23, 8:00 PMjournaltime_stop

     Agent 5 — Dip Buyer (Evolving) closed long 3 @ $556.34 (-$1.60)

     Time stop: held 101 ≥ 90 days

170. ▣Aug 3, 8:00 PMjournalstop

     Agent 9 — Bear Equity closed short 18 @ $614.18 (-$1,463.76)

     intraday stop sweep

171. ▢Aug 3, 8:00 PMjournal

     Agent 9 — Bear Equity opened short 17 @ $588.11

172. ▢Jul 26, 8:00 PMjournal

     Agent 7 — Day Trader opened long 5 @ $559.56

173. ▣Jul 26, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 5 @ $555.52 (-$20.20)

     EOD forced close — day trader never carries overnight

174. ▢May 14, 8:00 PMjournal

     Agent 9 — Bear Equity opened short 18 @ $532.86

175. ▢May 14, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 3 @ $556.87